Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Zydus Lifesciences Ltd.
Change Company   
BSE Code 532321
ISIN Demat INE010B01027
Book Value 235.25
NSE Code ZYDUSLIFE
Dividend Yield % 0.09
Market Cap 1110882.32
P/E 31.21
EPS 35.38
Face Value 1  
29-May-2026 Corporate Action-Updates on Buy back
27-May-2026 Corporate Action-Updates on Buy back
20-May-2026 Zydus Lifesciences soars on reporting 9% rise in ...
19-May-2026 Zydus Lifesciences reports 9% rise in Q4 consolid...
19-May-2026 Zydus Lifesciences informs about investor presen...
19-May-2026 Zydus Lifesciences informs about outcome of board...
19-May-2026 General Update On Buyback
14-May-2026 Zydus Lifesciences’ arm inks definitive pact to a...
14-May-2026 Zydus Lifesciences zooms as its arm inks definiti...
13-May-2026 Zydus Lifesciences informs about change in direct...
13-May-2026 Zydus Lifesciences informs about update on board ...
06-May-2026 USFDA concludes GMP surveillance inspection at Zy...
06-May-2026 Zydus Lifesciences informs about press release
05-May-2026 Zydus Lifesciences informs about updates
04-May-2026 Zydus Lifesciences shines as its arm acquires 100...
Page 1 of 6
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Scores| Policies of JFSL
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE| Rights and obligation| SARAL Form
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.